Ensysce Biosciences, Inc.

Equities

ENSC

US2936024056

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-23 EDT			5-day change	1st Jan Change
0.5888 ^USD	-7.54%		-3.81%	-44.45%

05-20	Sector Update: Health Care Stocks Softer Late Afternoon	MT
05-20	Sector Update: Health Care	MT

Ensysce Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

March 30, 2023 at 05:18 pm

Ensysce Biosciences, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 24.17 million compared to USD 29.08 million a year ago. Basic loss per share from continuing operations was USD 139.4401 compared to USD 355.6801 a year ago.

Latest news about Ensysce Biosciences, Inc.

Sector Update: Health Care Stocks Softer Late Afternoon	05-20	MT
Sector Update: Health Care	05-20	MT
Ensysce Biosciences Renews Collaboration with Quotient Sciences for Pain Killer Drug Study	05-20	MT
Ensysce Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Transcript : Ensysce Biosciences, Inc., Q4 2023 Earnings Call, Mar 21, 2024	03-21
Ensysce Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-15	CI
Ensysce Biosciences Announces Successful Meeting with Fda for Pf614-Mpar, A Next Generation Opioid with Overdose Protection	02-21	CI
Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript	02-15	CI
Ensysce Shares Rally After FDA Feedback on Pain Medication	01-31	DJ
Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain	01-31	CI
Ensysce Biosciences Shares Up 39% on FDA Breakthrough Designation for PF614-MPAR	01-23	DJ
Wall Street Set to Open Flat as Investors Eye Key Manufacturing Index	01-23	MT
Ensysce Biosciences, Inc. Announces Key Efficacy Data for Lead Analgesic	12-14	CI
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-Development of BupiZenge in the United States	11-28	CI
Ensysce Biosciences, Inc. announced that it has received $1.7 million in funding	11-27	CI
Ensysce Biosciences, Inc. Announces Enrollment Completion for PF614-201 Clinical Study	11-16	CI
Ensysce Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Ensysce Biosciences, Inc. announced that it expects to receive $1.7 million in funding	23-10-22	CI
Top Premarket Gainers	23-10-09	MT
Ensysce Biosciences, Inc. Announces Completion of Site Initiation Visit for PF614-201 Clinical Study	23-09-26	CI
HC Wainwright Adjusts Ensysce Biosciences Price Target to $7 From $9, Maintains Buy Rating	23-09-25	MT
Transcript : Ensysce Biosciences, Inc. - Special Call	23-09-21
Ensysce Biosciences Completes Scale Up Manufacture of PF614 to Support Phase 3 Studies	23-09-14	CI
Transcript : Ensysce Biosciences, Inc. - Shareholder/Analyst Call	23-08-24
Certain Common Stock of Ensysce Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 16-AUG-2023.	23-08-15	CI

Chart Ensysce Biosciences, Inc.

Duration

Period

More charts

Company Profile

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. The TAAP platform is designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription opioid drug abuse. The MPAR platform, when combined with its TAAP prodrugs, is designed to seek to prevent abuse of prescription drugs but also to reduce overdose occurrences. Additionally, nafamostat di-mesylate (nafamostat), which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Ensysce Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ENSYSCE BIOSCIENCES, INC.	-44.45%	4.83M
MODERNA, INC.	+64.92%	62.59B
IQVIA HOLDINGS INC.	-1.85%	41.18B
LONZA GROUP AG	+44.76%	40.29B
CELLTRION, INC.	-8.93%	27.9B
ICON PUBLIC LIMITED COMPANY	+13.05%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.96%	19.09B
BIO-TECHNE CORPORATION	+4.21%	13.08B
UNITED THERAPEUTICS CORPORATION	+25.74%	12.26B
MEDPACE HOLDINGS, INC.	+27.42%	12.05B

Other Biotechnology & Medical Research